Reduced dose radiation therapy for indolent non-Hodgkin lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II trial evaluates the safety and effectiveness of reduced dose radiation therapy compared to standard dose radiation in patients with indolent non-Hodgkin lymphoma. The study aims to determine if a lower radiation dose can reduce acute toxicity while maintaining treatment efficacy. Participants will receive radiation in fewer fractions and will be monitored for side effects, quality of life, and treatment response. Additionally, biopsies and imaging studies will be conducted to explore correlations between biological markers and treatment outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* Histological confirmation of indolent B-cell lymphoma that can include any of the following:

  * Follicular lymphoma (grade 1 or 2 or 3A)
  * Marginal zone lymphoma (nodal or extranodal)
  * Follicle center lymphoma
* Any stage disease
* Initial, refractory, or relapsed disease. If relapse involves the site to be treated there must be evidence of disease progression
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 3
* Negative pregnancy test done ≤ 7 days prior to registration, for persons of childbearing potential only
* Provide written informed consent
* Ability to complete questionnaire(s) by themselves or with assistance
* Willing to return to enrolling institution for follow-up visits (during the active monitoring phase of the study). Virtual visits can also be considered as an option for applicable items
* Confirmation from radiation oncologist of suitability to participate in study

Exclusion Criteria:

* Any of the following:

  * Pregnant women
  * Nursing women
  * Women of childbearing potential who are unwilling to employ adequate contraception
* T-cell lymphoma
* Receiving treatment for small and chronic lymphocytic lymphoma
* Grade 3B follicular lymphoma

Where it's running

• Mayo Clinic in Arizona
  Scottsdale, Arizona, United States Recruiting
• Mayo Clinic in Florida
  Jacksonville, Florida, United States Recruiting
• Mayo Clinic Health System in Albert Lea
  Albert Lea, Minnesota, United States Recruiting
• Mayo Clinic in Rochester
  Rochester, Minnesota, United States Recruiting
• Mayo Clinic Health System-Eau Claire Clinic
  Eau Claire, Wisconsin, United States Recruiting
• Mayo Clinic Health System-Franciscan Healthcare
  La Crosse, Wisconsin, United States Recruiting

Study contacts

• Principal investigator: Brad S. Hoppe, MD, MPH — Mayo Clinic
• Study coordinator: Clinical Trials Referral Office
• Email: mayocliniccancerstudies@mayo.edu
• Phone: 855-776-0015

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Genetically engineered CAR T-cells for treating certain blood cancers

  This study is testing a new type of treatment using specially modified immune cells to see if they can help people with certain blood cancers that haven't responded to other treatments.

  Recruiting at 2 sites Phase 1 Ohio State University Comprehensive Cancer Center · Columbus, Ohio and 1 other locations · NCT05418088

• Treatment for relapsed or refractory B-cell lymphoma using SynKIR-310

  This study is testing a new treatment called SynKIR-310 to see if it can help adults with relapsed or refractory B-cell lymphoma feel better.

  Recruiting at 5 sites Phase 1 Verismo Therapeutics · Denver, Colorado and 4 other locations · NCT06544265

• Using Ga-68-CXCR4 PET/CT to improve detection of indolent B-cell lymphoma

  This study is testing a new type of PET scan to see if it can better detect and monitor slow-growing B-cell lymphoma in patients compared to the current method.

  Recruiting Phase 2 Koo Foundation Sun Yat-Sen Cancer Center · Taipei, Beitou · NCT06461182

• Combination treatment for indolent B-cell non-Hodgkin lymphoma

  This study is testing a new combination of treatments for people with indolent B-cell non-Hodgkin lymphoma that hasn't responded to previous therapies to see if it can help them.

  Recruiting at 13 sites Phase 1/2 BioInvent International AB · Atlanta, Georgia and 26 other locations · NCT03571568

• Epcoritamab for B-cell lymphoma patients not fully responding to CAR-T therapy

  This study is testing if a new treatment called epcoritamab can help people with B-cell lymphoma who didn't fully respond to CAR-T therapy feel better and improve their chances of survival.

  Recruiting Phase 2 Academic and Community Cancer Research United · Rochester, Minnesota and 5 other locations · NCT06238648

• Combining three anti-cancer drugs for treating relapsed or refractory diffuse large B-cell lymphoma

  This study is testing a combination of three cancer drugs to see if they can help people with tough-to-treat diffuse large B-cell lymphoma feel better and respond to treatment.

  Recruiting at 8 sites Phase 1 National Cancer Institute (NCI) · Duarte, California and 7 other locations · NCT06015880

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.